deibrotide (DEFITELIO°)

October 2015
Prescrire International;Oct2015, Vol. 24 Issue 164, p235
No abstract available.


Related Articles

  • Five treatments get the go-ahead for use in Scotland.  // PharmacoEconomics & Outcomes News;Jun2014, Vol. 705 Issue 1, p10 

    The article reports on the Scottish Medicines Consortium's recommendation on the use of five treatments including sofosbuvir (Sovaldi), canagliflozin (Invokana), and defibrotide (Defitelio), for various medical conditions in Scotland as of June 9, 2014.

  • Approved.  // WHO Drug Information;2016, Vol. 30 Issue 2, p215 

    The article offers information on several drugs approved by the U.S. Food and Drug Adminsitration and the European Medicines Agency as of April 2016 including Ocacliva, an melancholic acid for primary biliary cholangitis, Defitelio, defibrotide sodium for rare complication in stem cell...

  • Lilly's Taltz Approved For Plaque Psoriasis.  // Chain Drug Review;4/18/2016, Vol. 38 Issue 7, p248 

    The article offers news briefs related to the U.S. pharmaceutical industry including the approval by the Food and Drug Administration to Eli Lilly and Co.'s Taltz injection and Jazz Pharmaceuticals' Defitelio, and the final acquisition of Vantage Oncology LLC and Biologics Inc. by McKesson Corp.

  • Gentium's Defibrotide Brings 2Q Sales Record as Launch Looms. Sheridan, Cormac // BioWorld Today;8/14/2013, Vol. 24 Issue 155, p1 

    The article reports on the high sales record posted by Gentium SpA for its Defitelio (defibrotide) drug product in the second quarter of 2013. It describes the mechanism of action of the drug used for the prevention or treatment of hepatic veno-occlusive disease (VOD) in patients undergoing...

  • Other News To Note.  // BioWorld Today;10/23/2013, Vol. 24 Issue 204, p2 

    This section offers global pharmaceutical news briefs. Beatica AB expanded its collaboration with Boehringer Ingelheim GmbH to use its fragment-based platform to identify selective hits against oncology-relevant kinases of interest to Boehringer. Gentium SpA obtained a marketing authorization...

  • Jazz paying $1B for Gentium; gains rights to defibrotide. Sheridan, Cormac // BioWorld Today;12/23/2013, Vol. 24 Issue 245, p1 

    The article reports on the acquisition of 57 percent of the shares of Gentium SpA by Jazz Pharmaceuticals plc. It talks about the Defitelio (defibrotide) drug of Gentium which has been approved by the European Union (EU) and will be launched at the European Society for Blood and Bone Marrow...

  • Defibrotide: A Review of Its Use in Severe Hepatic Veno-Occlusive Disease Following Haematopoietic Stem Cell Transplantation. Keating, Gillian // Clinical Drug Investigation;Dec2014, Vol. 34 Issue 12, p895 

    Defibrotide (Defitelio) was recently approved in the EU for the treatment of severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstructive syndrome, in haematopoietic stem cell transplantation (HSCT) therapy. It is indicated in adults, adolescents, children and infants over 1...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics